Cite
Timotheadou E, Kalogeras KT, Koliou GA, et al. Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Transl Oncol. 2017;10(4):589-598doi: 10.1016/j.tranon.2017.05.006.
Timotheadou, E., Kalogeras, K. T., Koliou, G. A., Wirtz, R. M., Zagouri, F., Koutras, A., Veltrup, E., Christodoulou, C., Pentheroudakis, G., Tsiftsoglou, A., Papakostas, P., Aravantinos, G., Venizelos, V., Pectasides, D., Kosmidis, P., Karanikiotis, C., Markopoulos, C., Gogas, H., & Fountzilas, G. (2017). Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Translational oncology, 10(4), 589-598. https://doi.org/10.1016/j.tranon.2017.05.006
Timotheadou, Eleni, et al. "Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy." Translational oncology vol. 10,4 (2017): 589-598. doi: https://doi.org/10.1016/j.tranon.2017.05.006
Timotheadou E, Kalogeras KT, Koliou GA, Wirtz RM, Zagouri F, Koutras A, Veltrup E, Christodoulou C, Pentheroudakis G, Tsiftsoglou A, Papakostas P, Aravantinos G, Venizelos V, Pectasides D, Kosmidis P, Karanikiotis C, Markopoulos C, Gogas H, Fountzilas G. Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Transl Oncol. 2017 Aug;10(4):589-598. doi: 10.1016/j.tranon.2017.05.006. Epub 2017 Jun 27. PMID: 28666187; PMCID: PMC5491451.
Copy
Download .nbib